Monte Rosa Therapeutics Rule of 40

Mitä Monte Rosa Therapeutics tekee? Monte Rosa Therapeutics Inc, headquartered in Boston, Massachusetts, operates in the Health Care sector within the Biotechnology industry. The company employs 150 full-time employees and went public on June 24, 2021. It focuses on developing precision medicines, particularly molecular glue degraders (MGDs), which selectively target proteins for degradation using the body's natural mechanisms. Monte Rosa has developed a platform called QuEEN (Quantitative and Engineered Elimination of Neosubstrates) to support its MGD discovery and development. Its lead product candidate, MRT-2359, is an orally bioavailable MGD targeting GSPT1 for potential treatment of MYC-driven tumors, including metastatic non-small cell lung cancer and small cell lung cancer. Monte Rosa Therapeutics on yksi Eurpooliin suosituimmista yhtiöistä.